F M Investments LLC Reduces Position in Eli Lilly and Company (NYSE:LLY)

F M Investments LLC lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 17.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 37,502 shares of the company's stock after selling 7,679 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of F M Investments LLC's holdings, making the stock its 21st biggest holding. F M Investments LLC's holdings in Eli Lilly and Company were worth $28,952,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of LLY. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock worth $57,320,226,000 after purchasing an additional 475,530 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock worth $13,389,651,000 after buying an additional 291,875 shares during the period. Wellington Management Group LLP boosted its stake in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares during the period. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $8,407,908,000. Finally, Fisher Asset Management LLC boosted its position in Eli Lilly and Company by 3.5% during the 4th quarter. Fisher Asset Management LLC now owns 5,236,108 shares of the company's stock worth $4,042,276,000 after acquiring an additional 178,007 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

LLY has been the subject of several research reports. Morgan Stanley reduced their price target on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research note on Friday, January 17th. Citigroup lowered their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,012.00.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $9.28 during trading on Monday, reaching $741.69. 1,340,645 shares of the company's stock were exchanged, compared to its average volume of 3,378,646. The company has a market cap of $703.25 billion, a P/E ratio of 63.34, a PEG ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm's 50-day moving average price is $837.05 and its 200 day moving average price is $822.87.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.